Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.4069
-0.0467 (-10.30%)
Nov 16, 2026, 4:00 PM EST - Market closed

Kairos Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
3.83.441.931.630.481.76
Research & Development
2.732.140.410.080.090.18
Operating Expenses
6.535.572.341.710.571.94
Operating Income
-6.53-5.57-2.34-1.71-0.57-1.94
Interest Expense
---0.19-0.1-0.46-0.16
Interest & Investment Income
0.140.13----
Other Non Operating Income (Expenses)
---0.67--0.02-0.04
EBT Excluding Unusual Items
-6.39-5.45-3.2-1.81-1.05-2.15
Other Unusual Items
--0.6---
Pretax Income
-6.39-5.45-2.6-1.81-1.05-2.15
Net Income
-6.39-5.45-2.6-1.81-1.05-2.15
Net Income to Common
-6.39-5.45-2.6-1.81-1.05-2.15
Net Income Growth
------
Shares Outstanding (Basic)
332111
Shares Outstanding (Diluted)
332111
Shares Change
31.01%62.27%9.38%1.42%11.86%-3.12%
EPS (Basic)
-2.06-2.07-1.60-1.22-0.72-1.64
EPS (Diluted)
-2.06-2.07-1.60-1.22-0.72-1.64
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EBITDA
-6.43-5.41-2.18-1.55-0.41-1.85
D&A For EBITDA
0.10.160.160.160.160.1
EBIT
-6.53-5.57-2.34-1.71-0.57-1.94
SEC Filings: 10-K · 10-Q